Investigator Initiated Studies (IIS) supports investigators conducting clinical studies of Genentech medicines to deepen understanding of treatments, improve patient care and generate disease-related research.
Funder: Roche
Due Dates: November 21, 2026 (CNS Lymphoma—Glofitamab proposals)
Funding Amounts: Medicines, funding, materials and/or information; funding evaluated against local fair market value
Summary: Genentech supports investigator-led clinical studies that advance understanding of its medicines, improve patient care and generate disease-related research.
Key Information: Sponsors assume sole responsibility for study conduct and management and must publish results in a scientific journal.
Genentech’s Investigator Initiated Studies (IIS) program welcomes unsolicited proposals from qualified sponsors with promising ideas in its strategic research areas. It considers scientifically sound studies that enhance understanding of its medicines, improve patient care and spark new disease-related research. Medical science personnel can guide sponsors from concept pre-approval through submission of the final protocol and budget.
Supported research includes Phase I–IV interventional studies of approved or investigational uses of Genentech medicines, clinical observational studies and real-world evidence, and clinical studies requesting medicines only. Studies are initiated, developed, designed and managed by the sponsor. US-based investigators use Genentech’s IIS portal; investigators outside the USA are directed to Roche’s international IIS portal.